Your browser doesn't support javascript.
loading
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner, Karoline V; Schneeweiss, Mathias; Eisenwort, Gregor; Berger, Daniela; Herrmann, Harald; Blatt, Katharina; Greiner, Georg; Byrgazov, Konstantin; Hoermann, Gregor; Konopleva, Marina; Waliul, Islam; Cumaraswamy, Abbarna A; Gunning, Patrick T; Maeda, Hiroshi; Moriggl, Richard; Deininger, Michael; Lion, Thomas; Andreeff, Michael; Valent, Peter.
Afiliação
  • Gleixner KV; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria karoline.gleixner@meduniwien.ac.at.
  • Schneeweiss M; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Eisenwort G; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Berger D; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Herrmann H; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.
  • Blatt K; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Greiner G; Department of Radiation Therapy, Medical University of Vienna, Austria.
  • Byrgazov K; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.
  • Hoermann G; Department of Laboratory Medicine, Medical University of Vienna, Austria.
  • Konopleva M; Children's Cancer Research Institute (CCRI), Vienna, Austria.
  • Waliul I; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Cumaraswamy AA; Department of Laboratory Medicine, Medical University of Vienna, Austria.
  • Gunning PT; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Maeda H; Institute of Drug Delivery Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan.
  • Moriggl R; Department of Chemistry, University of Toronto, Canada.
  • Deininger M; Department of Chemistry, University of Toronto, Canada.
  • Lion T; Institute of Drug Delivery Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan.
  • Andreeff M; Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.
  • Valent P; Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.
Haematologica ; 102(9): 1519-1529, 2017 09.
Article em En | MEDLINE | ID: mdl-28596283
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Sistemas de Liberação de Medicamentos / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Fator de Transcrição STAT3 / Fator de Transcrição STAT5 Idioma: En Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Áustria
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Sistemas de Liberação de Medicamentos / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Fator de Transcrição STAT3 / Fator de Transcrição STAT5 Idioma: En Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Áustria